An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Lithium (Primary)
- Indications Psychotic disorders; Schizophrenia
- Focus Therapeutic Use
- 30 May 2013 Biomarkers information updated
- 29 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Oct 2005 New trial record.